Carolina trial results

Lower cost would favor the former category, while less hypoglycemia and weight gain would favor the latter category. JAMA ; Description: The goal of the trial was to evaluate the dipeptidyl peptidase-4 DPP-4 inhibitor linagliptin compared with the sulfonylurea glimepiride among patients with type 2 diabetes and elevated cardiovascular risk. Total number of enrollees: 6, Duration of follow-up: median 6.

Supplement 4. Supplement 5. Data sharing statement. Diabetes Care. J Am Coll Cardiol. Geneva, Switzerland: World Health Organization; Long-term trends in antidiabetes drug usage in the U. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: systematic review and meta-analysis.

Clin Invest Med. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. BMC Endocr Disord. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: II: mortality results.

PubMed Google Scholar. Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a Bayesian meta-analysis of survival data. Diabetes Obes Metab. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.

Eur Heart J. Tradjenta linagliptin tablets prescribing information. Boehringer Ingelheim Pharmaceuticals website. Accessed June 25, Diab Vasc Dis Res. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.

Pharmacogenomics J. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes.

US Food and Drug Administration website. Published December Composite primary end points in cardiovascular outcomes trials involving type 2 diabetes patients: should unstable angina be included in the primary end point? Center for Drug Evaluation and Research. Meeting expectations to exclude a CV risk margin of 1. In Application number: Orig1s summary review, page A multiple testing procedure for clinical trials.

Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. Google Scholar Crossref. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial.

FDA guidance on antihyperglyacemic therapies for type 2 diabetes: one decade later. This randomized clinical trial compares the effects of the dipeptidyl peptidase 4 inhibitor linagliptin vs placebo plus usual care on cardiovascular CV and renal outcomes in adults with type 2 diabetes and high CV and renal risk. This cohort study uses data from the National Veterans Health Administration, Medicare, Medicaid, and National Death Index to compare major adverse cardiovascular events among patients with diabetes and reduced kidney function who continued treatment with metformin or sulfonylurea.

Christianne L. Hackstadt, PhD; Adriana M. Save Preferences. Privacy Policy Terms of Use. View Correction. This Issue. Views 64, Citations View Metrics.

Twitter Facebook More LinkedIn. Original Investigation. Espeland, PhD 8 ; Hans J. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www. Intended audiences This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.

Diabetol Int. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; The nature, extent and purpose of the collection and processing of personal data depend on the actions of the user during the visit of this website. In any event, collection and processing of personal data will only take place conformable to the applicable law.

When using the website, temporarily certain data, including data sent by your browser IP address, cookies, referring web page, time and date, content viewed will be stored. Boehringer Ingelheim will also use this information in pseudonymized form in order to design and improve the website in a needs-based manner. You can find more information regarding this in the "Cookies" section. Boehringer Ingelheim only transfers personal data to third parties when you have expressly given your consent, when required to deliver services that you want to use, or when the data transfer is otherwise justified under the applicable law and it is made sure that your legitimate interests are observed.

Boehringer Ingelheim undertakes to provide an adequate protection of personal data transferred outside of the European Union, regardless whether such data is processed by other Boheringer Ingelheim group companies or other third parties. On your request, we will inform you in writing or electronically whether and what data relating to you Boehringer Ingelheim has stored and will review any requests you may have to delete, correct or block personal data.

Please send your request to:. Such consent can be withdrawn at any time with effect for the future by mail or email to the above addresses.

This website uses cookies. A cookie is a small text file, downloaded on to a device when the user accesses certain websites. Cookies are widely used in order to make websites work, or work more efficiently, as well as to recognize your device on subsequent visits to provide information to the owners of the site. If you do not want cookies on your computer or other device , you can deactivate them in your browser settings.